• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌中涉及p53信号通路的相关网络。

Relevant Networks involving the p53 Signalling Pathway in Renal Cell Carcinoma.

作者信息

Villaamil V Medina, Gallego G Aparicio, Caínzos I Santamarina, Ruvira L Valbuena, Valladares-Ayerbes M, Aparicio L M Antón

机构信息

INIBIC, CHU A Coruña. A Coruña, Spain;

出版信息

Int J Biomed Sci. 2011 Dec;7(4):273-82.

PMID:23675247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3614848/
Abstract

INTRODUCTION

Renal cell carcinoma is the most common type of kidney cancer. A better understanding of the critical pathways and interactions associated with alterations in renal function and renal tumour properties is required. Our final goal is to combine the knowledge provided by a regulatory network with experimental observations provided by the dataset.

METHODS

In this study, a systems biology approach was used, integrating immunohistochemistry protein expression profiles and protein interaction information with the STRING and MeV bioinformatics tools. A group consisting of 80 patients with renal cell carcinoma was studied. The expression of selected markers was assessed using tissue microarray technology on immunohistochemically stained slides. The immunohistochemical data of the molecular factors studied were analysed using a parametric statistical test, Pearson's correlation coefficient test.

RESULTS

Bioinformatics analysis of tumour samples resulted in 2 protein networks. The first network consists of proteins involved in the angiogenesis pathway and the apoptosis suppressor, BCL2, and includes both positive and negative correlations. The second network shows a negative interaction between the p53 tumour suppressor protein and the glucose transporter type 4.

CONCLUSION

The comprehensive pathway network will help us to realise the cooperative behaviours among pathways. Regulation of metabolic pathways is an important role of p53. The pathway involving the tumour suppressor gene p53 could regulate tumour angiogenesis. Further investigation of the proteins that interact with this pathway in this type of tumour may provide new strategies for cancer therapies to specifically inhibit the molecules that play crucial roles in tumour progression.

摘要

引言

肾细胞癌是最常见的肾癌类型。需要更好地理解与肾功能改变和肾肿瘤特性相关的关键途径及相互作用。我们的最终目标是将调控网络提供的知识与数据集提供的实验观察结果相结合。

方法

在本研究中,采用了系统生物学方法,将免疫组织化学蛋白质表达谱和蛋白质相互作用信息与STRING和MeV生物信息学工具相结合。对一组由80例肾细胞癌患者组成的样本进行了研究。使用组织微阵列技术在免疫组织化学染色的玻片上评估所选标志物的表达。使用参数统计检验(Pearson相关系数检验)分析所研究分子因子的免疫组织化学数据。

结果

对肿瘤样本的生物信息学分析产生了2个蛋白质网络。第一个网络由参与血管生成途径的蛋白质和凋亡抑制因子BCL2组成,包括正相关和负相关。第二个网络显示p53肿瘤抑制蛋白与4型葡萄糖转运蛋白之间存在负相互作用。

结论

全面的途径网络将有助于我们认识途径之间的协同行为。代谢途径的调控是p53的重要作用。涉及肿瘤抑制基因p53的途径可调节肿瘤血管生成。进一步研究在这类肿瘤中与该途径相互作用蛋白质可能为癌症治疗提供新策略,以特异性抑制在肿瘤进展中起关键作用的分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/099ee706cfe9/IJBS-7-273_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/30d8246ef9d7/IJBS-7-273_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/2a6508502e9c/IJBS-7-273_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/c98c5a5f352b/IJBS-7-273_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/099ee706cfe9/IJBS-7-273_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/30d8246ef9d7/IJBS-7-273_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/2a6508502e9c/IJBS-7-273_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/c98c5a5f352b/IJBS-7-273_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a2c/3614848/099ee706cfe9/IJBS-7-273_F4.jpg

相似文献

1
Relevant Networks involving the p53 Signalling Pathway in Renal Cell Carcinoma.肾细胞癌中涉及p53信号通路的相关网络。
Int J Biomed Sci. 2011 Dec;7(4):273-82.
2
Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.基于基因集富集分析的 clear cell 肾细胞癌基因表达分析用于生物统计学管理。
BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16.
3
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.INGN 201:腺病毒载体p53、Ad5CMV-p53、腺病毒p53、p53基因疗法——英特洛根公司,RPR/INGN 201。
Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005.
4
Integrated Genome-Wide Analysis of Gene Expression and DNA Copy Number Variations Highlights Stem Cell-Related Pathways in Small Cell Esophageal Carcinoma.基因表达与DNA拷贝数变异的全基因组综合分析揭示了小细胞食管癌中与干细胞相关的信号通路。
Stem Cells Int. 2018 Aug 30;2018:3481783. doi: 10.1155/2018/3481783. eCollection 2018.
5
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.p73(一种与p53肿瘤抑制蛋白相关的新型蛋白质)在肝内胆管细胞癌中的表达及细胞凋亡
Br J Cancer. 1999 Jun;80(7):1069-74. doi: 10.1038/sj.bjc.6690465.
6
Investigation of tumour supressor protein p53 in renal cell carcinoma patients.肾细胞癌患者中肿瘤抑制蛋白p53的研究
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(1):44-9. doi: 10.5507/bp.2012.035. Epub 2012 Jun 1.
7
INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.INGN 201:腺病毒介导的p53基因疗法、Ad5CMV-p53、腺病毒p53、INGN 101、p53基因疗法——英特洛根公司,RPR/INGN 201。
BioDrugs. 2003;17(3):216-22. doi: 10.2165/00063030-200317030-00010.
8
Searching for Hif1-α interacting proteins in renal cell carcinoma.在肾细胞癌中寻找 Hif1-α 相互作用蛋白。
Clin Transl Oncol. 2012 Sep;14(9):698-708. doi: 10.1007/s12094-012-0857-4. Epub 2012 Aug 28.
9
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer.bcl-2作为非小细胞肺癌肿瘤血管生成抑制因子的潜在作用。
Int J Cancer. 1997 Dec 19;74(6):565-70. doi: 10.1002/(sici)1097-0215(19971219)74:6<565::aid-ijc1>3.0.co;2-s.
10
An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma.一项综合转录组分析揭示了p53调控的鼻咽癌miRNA、mRNA和lncRNA网络。
Tumour Biol. 2016 Mar;37(3):3683-95. doi: 10.1007/s13277-015-4156-x. Epub 2015 Oct 13.

引用本文的文献

1
Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma.肾细胞癌不同组织病理亚型中 Hippo 信号活性的异质性。
J Cell Mol Med. 2023 Jan;27(1):66-75. doi: 10.1111/jcmm.17632. Epub 2022 Dec 7.

本文引用的文献

1
Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters.葡萄糖转运蛋白表达及果糖在肾细胞癌中的潜在作用:与病理参数的相关性
Mol Med Rep. 2010 Jul-Aug;3(4):575-80. doi: 10.3892/mmr_00000300.
2
Impact of genetics on the diagnosis and treatment of renal cancer.遗传学对肾癌的诊断和治疗的影响。
Curr Urol Rep. 2011 Feb;12(1):47-55. doi: 10.1007/s11934-010-0156-y.
3
Designing logical rules to model the response of biomolecular networks with complex interactions: an application to cancer modeling.
设计逻辑规则来模拟具有复杂相互作用的生物分子网络的响应:在癌症建模中的应用。
IEEE/ACM Trans Comput Biol Bioinform. 2011 Sep-Oct;8(5):1223-34. doi: 10.1109/TCBB.2010.71.
4
p53 regulation of metabolic pathways.p53 对代谢途径的调节。
Cold Spring Harb Perspect Biol. 2010 Apr;2(4):a001040. doi: 10.1101/cshperspect.a001040. Epub 2009 Dec 2.
5
Disease candidate gene identification and prioritization using protein interaction networks.利用蛋白质相互作用网络进行疾病候选基因的识别与优先级排序。
BMC Bioinformatics. 2009 Feb 27;10:73. doi: 10.1186/1471-2105-10-73.
6
Dynamic modularity in protein interaction networks predicts breast cancer outcome.蛋白质相互作用网络中的动态模块化可预测乳腺癌预后。
Nat Biotechnol. 2009 Feb;27(2):199-204. doi: 10.1038/nbt.1522. Epub 2009 Feb 1.
7
Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer.晚期人类结肠癌特异性蛋白质相互作用子网的发现与评分
Mol Cell Proteomics. 2009 Apr;8(4):827-45. doi: 10.1074/mcp.M800428-MCP200. Epub 2008 Dec 19.
8
STRING 8--a global view on proteins and their functional interactions in 630 organisms.STRING 8——关于630种生物中蛋白质及其功能相互作用的全局视图。
Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6. doi: 10.1093/nar/gkn760. Epub 2008 Oct 21.
9
Recent advances in p53 research: an interdisciplinary perspective.p53研究的最新进展:跨学科视角
Cancer Gene Ther. 2009 Jan;16(1):1-12. doi: 10.1038/cgt.2008.69. Epub 2008 Sep 19.
10
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.在p53基因缺失的乳腺癌小鼠模型中鉴定肿瘤起始细胞。
Cancer Res. 2008 Jun 15;68(12):4674-82. doi: 10.1158/0008-5472.CAN-07-6353.